Dr. Petr Kavan

McGill Young Adults Oncology Program

Dr. Kavan, an internationally recognized clinician scientist, is currently practicing as a medical Oncologist at Jewish General Hospital and McGill University. He completed his medical school training, his internship and residency in Pediatrics and Medicine and his fellowship in Oncology at Charles University in Prague, Czech Republic.

He later became a visiting fellow and scientist for Baylor College of Medicine and Texas Children’s Cancer Center as well as a visiting scientist in Memphis, USA ; Hannover, Germany; Leeds, UK; Paris, France; and Vancouver, British Columbia. After which he completed his PhD in Oncology Bone Marrow Transplants in 2001.

With his efforts, the creation of the Adolescent and Young Adult Cancer Program within the McGill University teaching hospitals, based at the Segal Cancer Centre of the Jewish General Hospital was established.

dont miss

Comparing Clinical Characteristics and Outcomes of Young-onset and Late-Onset Colorectal Cancer

Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients.

EVEN MORE SEMINARS

  • Andras Szasz: Speaking at the Oncology Convention

    Andras Szasz
    St. Istvan University

    Modulated electrohyperthermia (mEHT) for advanced malignant tumors

  • Professor Hisham Mehanna: Speaking at the Oncology Convention

    Professor Hisham Mehanna
    InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham

    Clinical trials that change patient care and the lessons learnt

  • Dr Bernadette A Lavery: Speaking at the Oncology Convention

    Dr Bernadette A Lavery
    GenesisCare

    Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment

  • Dr Antonia Lavorata: Speaking at the Oncology Convention

    Dr Antonia Lavorata
    GenesisCare

    Surface-Guided Radiotherapy and Optimal Breast Cancer Treatment

  • Stuart Dollow: Speaking at the Oncology Convention

    Stuart Dollow
    Vermilion Life Sciences Ltd

    Reengineering Medicines Development